Developed by MedGenome , ThyroTrack is a next-generation sequencing (NGS)-based thyroid prognostication panel designed to uncover the genetic profile of thyroid nodules using Thyroid FNAC in RNA Later fluid or FFPE Block samples. By analysing clinically relevant mutations and gene fusions, ThyroTrack helps clinicians improve the evaluation of indeterminate thyroid nodules and supports informed treatment decisions.
Developer of ThyroTrack and leader in advanced clinical genomics.
Thyroid FNAC in RNA Later fluid or FFPE Block collected for molecular analysis.
46 genes for SNVs & InDels and 23 fusion genes are analysed using advanced NGS technology.
Comprehensive genomic findings support thyroid nodule risk assessment.
Thyroid nodules are initially classified using the Bethesda System based on FNAC findings. While most nodules are clearly benign or malignant, approximately 10–30% remain indeterminate and require advanced molecular testing such as ThyroTrack for better clinical decision-making.
FNAC successfully classifies most thyroid nodules as benign or malignant, enabling standard clinical management.
Molecular profiling with ThyroTrack helps evaluate indeterminate thyroid nodules by detecting clinically significant mutations and gene fusions.
From tumour tissue analysis to AI-driven risk prediction, every step is designed to deliver accurate and personalized recurrence risk assessment.
A thyroid nodule is detected during clinical examination or imaging.
Fine Needle Aspiration Cytology (FNAC) is performed to evaluate the nodule.
FNAC shows an indeterminate or suspicious Bethesda classification.
NGS analyses 46 genes for SNVs & InDels and 23 fusion genes.
Molecular findings support diagnosis and personalized treatment planning.
ThyroTrack uses targeted Next-Generation Sequencing (NGS) to analyse clinically significant genes associated with thyroid cancer. The panel detects both small genetic variants and clinically actionable gene fusions for comprehensive molecular profiling.
Detection of clinically relevant Single Nucleotide Variants and Insertions/Deletions.
Identification of clinically significant gene fusions associated with thyroid malignancies.
Improve thyroid nodule evaluation with ThyroTrack's advanced molecular testing. Reduce diagnostic uncertainty, support personalized patient management, and enable confident clinical decision-making with accurate genomic insights.